Inventor · disambiguated record
Avidor Shulman
Also filed as: SHULMAN AVIDOR
16 granted patents·14 pending applications·27 citations·filing 2008–2025
90Inventor score
Top patents by PatentIndex Score
30 records- 0188US11236162B2Antibodies against ILT2BIOND BIOLOGICS LTD·Filed 2021·Granted Feb 1, 2022·2 cites·14 claims
- 0287US10870842B2Stabilized alpha-galactosidase and uses thereofPROTALIX LTD·Filed 2019·Granted Dec 22, 2020·2 cites·20 claims
- 0384US9708595B2Stabilized alpha-galactosidase and uses thereofPROTALIX LTD·Filed 2015·Granted Jul 18, 2017·4 cites·20 claims
- 0484US9194011B2Stabilized alpha-galactosidase and uses thereofSHULMAN AVIDOR·Filed 2011·Granted Nov 24, 2015·8 cites·41 claims
- 0582US10280414B2Stabilized α-galactosidase and uses thereofPROTALIX LTD·Filed 2017·Granted May 7, 2019·3 cites·20 claims
- 0681US11225648B2Modified DNase and uses thereofPROTALIX LTD·Filed 2016·Granted Jan 18, 2022·4 cites·24 claims
- 0780US12071479B2Antibodies against ILT2 and use thereofBIOND BIOLOGICS LTD·Filed 2021·Granted Aug 27, 2024·1 cites·23 claims
- 0879US12385026B2Stabilized alpha-galactosidase and uses thereofPROTALIX LTD·Filed 2022·Granted Aug 12, 2025·0 cites·16 claims
- 0977US12139534B2Methods and compositions for decreasing soluble immune receptor CD28BIOND BIOLOGICS LTD·Filed 2019·Granted Nov 12, 2024·1 cites·10 claims
- 1077US9603907B2Dry powder formulations of dNase IPROTALIX LTD·Filed 2013·Granted Mar 28, 2017·2 cites·20 claims
- 1176US2024309094A1Methods and compositions for decreasing soluble immune receptor cd28BIOND BIOLOGICS LTD·Filed 2024·Application pending·0 cites
- 1275US2025388668A1Antibodies against ilt2 and use thereofBIOND BIOLOGICS LTD·Filed 2025·Application pending·0 cites
- 1369US12391755B2Methods of use for anti-ILT2 antibodiesBIOND BIOLOGICS LTD·Filed 2021·Granted Aug 19, 2025·0 cites·20 claims
- 1462US11814657B2Modified DNase and uses thereofPROTALIX LTD·Filed 2021·Granted Nov 14, 2023·0 cites·19 claims
- 1561US2025019441A1Treatment of cancer with anti-ilt2 antibodiesBIOND BIOLOGICS LTD·Filed 2024·Application pending·0 cites
- 1660US8742079B2Saccharide-containing protein conjugates and uses thereofSHULMAN AVIDOR·Filed 2008·Granted Jun 3, 2014·0 cites·43 claims
- 1759US2025277032A1Anti-ilt3 antibodies and use thereofBIOND BIOLOGICS LTD·Filed 2023·Application pending·0 cites
- 1858US2023221325A1Soluble cd28 levels after immunotherapyBIOND BIOLOGICS LTD·Filed 2023·Application pending·0 cites
- 1957US9603906B2Inhalable liquid formulations of DNase IPROTALIX LTD·Filed 2013·Granted Mar 28, 2017·0 cites·19 claims
- 2057US2024350648A1Intracellular delivery compositionsBIOND BIOLOGICS LTD·Filed 2024·Application pending·0 cites
- 2156US2024279335A1Cd28 shedding blocking agentsBIOND BIOLOGICS LTD·Filed 2022·Application pending·0 cites
- 2251US2014256017A1Saccharide-containing protein conjugates and uses thereofPROTALIX LTD·Filed 2014·Application pending·0 cites
- 2351US2024010706A1Immunomodulatory compostions and use thereofBIOND BIOLOGICS LTD·Filed 2021·Application pending·0 cites
- 2448US2023035730A1Soluble cd28 levels during immunotherapyBIOND BIOLOGICS LTD·Filed 2020·Application pending·0 cites
- 2548US2023041599A1Use of mmp inhibitionBIOND BIOLOGICS LTD·Filed 2020·Application pending·0 cites
- 2647US12503510B2Small shedding blocking agentsBIOND BIOLOGICS LTD·Filed 2020·Granted Dec 23, 2025·0 cites·20 claims
- 2746US2022153845A1A method for immunosuppressionBIOND BIOLOGICS LTD·Filed 2020·Application pending·0 cites
- 2844US2012328589A1Glucocerebrosidase multimers and uses thereofRUDERFER ILYA·Filed 2011·Application pending·0 cites
- 2940US2013017169A1Multimeric forms of therapeutic proteins and uses thereofPROTALIX LTD·Filed 2011·Application pending·0 cites
- 3039US9732333B2Nucleic acid construct for expression of alpha-galactosidase in plants and plant cellsSHULMAN AVIDOR·Filed 2011·Granted Aug 15, 2017·0 cites·24 claims
Join the waitlist — get patent alerts
Get an alert when Avidor Shulman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →